First published July 27, 2021.

Are all cancers linked to a single protein? Not quite, but a 2021 study gave the idea a memorable twist. A team led from the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto proposed that many cancers can be sorted into two broad groups depending on what one protein, called YAP, is doing inside the tumour cells. In one group YAP helps the cancer grow. In the other, YAP is switched off, and switching it back on can actually slow the cancer down.
The research, published in the journal Cancer Cell in July 2021, does not mean there is one cure for every cancer. It is a way of classifying tumours that may help scientists choose drugs more wisely and understand why some cancers change shape to escape treatment. Here is what the study found, and what it does and does not mean.
What is YAP?
YAP stands for Yes-associated protein. It is a transcriptional co-activator, a kind of molecular switch that helps turn sets of genes on. YAP does not bind DNA by itself. Instead it teams up with partner proteins called TEAD transcription factors, and together they control genes involved in cell growth, cell survival and how cells stick to their surroundings. A closely related protein, TAZ, works in much the same way.
Biologists have studied YAP for years as part of the Hippo signalling pathway, a system that helps organs know when to stop growing. In many common cancers, YAP is overactive and pushes cells to keep dividing. That is why it has long been seen as a possible drug target.
The two groups: YAPon and YAPoff
The Toronto-led team, working with colleagues at the University of Toronto, McGill University, the Hospital for Sick Children and Cincinnati Children’s Hospital, looked across a large range of cancer types and cell lines. They found that cancers tended to fall into one of two camps.
YAPon cancers
These express YAP and TAZ, and the proteins drive growth. This group includes many of the most common solid tumours, such as non-small cell lung cancer and prostate adenocarcinoma. The cells are usually “adherent”, meaning they attach firmly to surfaces and to each other.
YAPoff cancers
These have silenced YAP and TAZ. They include retinoblastoma (an eye cancer of young children), small cell lung cancer, neuroendocrine prostate cancer and other neural or neuroendocrine tumours, as well as some blood cancers. Many have lost a tumour-suppressor gene called RB1. Their cells tend to float loosely or attach only weakly.
The surprising part is that YAP behaves in opposite ways in the two groups. In YAPoff cancers, the researchers found that restoring YAP slowed growth in cell lines and in mouse models. In other words, the same protein that fuels one set of cancers acts as a brake in the other. The paper sums up this idea in one line: “YAP is thus pivotal across cancer, but in opposite ways, with therapeutic implications.”
How one protein can do opposite things
The difference seems to lie in which stretches of DNA YAP and TEAD act on. In YAPon cancers they work alongside a partner called AP-1 and activate programmes that drive cell division. In YAPoff cancer cells, when YAP is put back, it binds different control regions, linked to nerve-development factors, and switches on genes for adhesion molecules.
One of those is an integrin pair known as ITGAV/ITGB5. Integrins are proteins on the cell surface that help cells grip their surroundings. In the YAPoff cells, that integrin contributed to the growth-slowing effect: when the researchers blocked it, much of YAP’s braking action disappeared. The authors describe this as an anti-cancer integrin programme, in contrast with the pro-growth programme seen in YAPon tumours.
Why tumours switching sides matters
Cancers are not fixed. The team observed that some tumours can move from the YAPon state to the YAPoff state as they become neuroendocrine, something seen in both mouse and human prostate cancer. This kind of “lineage switching” is a known route to drug resistance: a cancer that responded to one treatment changes its identity and stops responding.
That is why the binary rule interested clinicians. Co-lead author Joel Pearson said in the institute’s press release that the rule “may expose strategies to treat many cancer types”, because having options for both states could help stop a cancer from escaping by flipping between them.
Possible drug vulnerabilities
The study also screened drugs and found the two groups had different weak points:
- YAPoff cancers were more sensitive to several classes of experimental and existing drugs, including inhibitors of NAMPT, aurora kinases, BCL-family proteins, HDACs, XPO1 and EIF4. Adding YAP back reduced that sensitivity.
- YAPon cancers were more sensitive to inhibitors of growth-signalling kinases such as SRC, EGFR, ERBB family members and BRAF, several of which are already used in clinics for specific cancers.
These are laboratory findings in cell lines and mice. They point to hypotheses that need testing in clinical trials before anyone can say they will help patients.
Common misunderstandings
“All cancers are caused by one protein.” No. Cancer arises from many different genetic and environmental changes. The study describes a pattern in how one regulator behaves, not a single cause.
“There are only two types of cancer.” Doctors still diagnose cancers by organ, cell type, stage and molecular markers. YAPon and YAPoff are research categories layered on top of those diagnoses, and the authors themselves note there may be exceptions to the binary model.
“A cure is around the corner.” The study offers a framework and drug leads, not a treatment. Some commentators in 2021 predicted that many cancers would become manageable long-term conditions within a couple of decades, thanks to targeted drugs and immunotherapy. That is an opinion about the field’s direction, not something this research shows.
What this means for patients
For now, nothing changes in how cancer is diagnosed or treated because of this study. Its value is for researchers designing future trials and for understanding why some aggressive cancers, such as small cell lung cancer and neuroendocrine prostate cancer, resist standard drugs. If you or someone close to you has cancer and wonders whether a new approach or trial might be suitable, talk to a doctor or the oncology team, who can explain what is available and appropriate.
The study is still a good example of how basic biology can reframe a big problem. Instead of treating YAP as simply a villain to block, it suggests that in some cancers the better move may be to turn it back on.
Sources: Pearson et al., Cancer Cell, 2021: Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity; Futurism, 19 July 2021: Doctors discover protein linking cancers.

COMMENTS